Skip to main content
OpenTrials
Completed

NCT Number: NCT02542332

Are Doctors Familiar With the Test Characteristics of Lung Cancer Screening?

This study evaluates whether doctors are familiar with the statistical background of lung cancer screening.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Background: Screening with low-dose CT scan can prevent three deaths due to lung cancer among 1000 high-risk individuals. However, false-positive results and radiation exposure are relevant disadvantages deserving accurate consideration. Candidates for screening can only make an autonomous decision if doctors inform them correctly about the pros and cons of the method. Therefore, this study aims to evaluate, whether doctors understand the test characteristics of lung cancer screening.

Methods: In a randomized trial, 556 doctors (members of the Austrian Respiratory Society) will be invited to answer questions regarding lung cancer screening based on online case vignettes. Half of the participants will be randomized to the group 'with data' and will receive the correct solutions in advance. The group 'without data' will have to rely on prior knowledge or estimate. Primary endpoint will be the between-groups difference in the estimated number of deaths preventable by screening. Secondary endpoints will be the between-groups differences in prevalence of lung cancer, prevalence of suspicious results, sensitivity, specificity, positive-predictive value, and false negative rate. Estimations will also be compared to actual values from the literature.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Doctors, who were in training or had a completed specialization training in:
  • Pneumonology
  • Internal Medicine
  • Surgery
  • or Radiology

Exclusion criteria

  • Doctors, with a specialized training in
  • ENT
  • Pediatrics
  • Pathology and doctors who had no e-mail address were excluded.

Treatment and study plan

With Data

Other

The participants received statistical data about lung cancer screening in order to help them answer the questionaire

Primary outcomes

  1. Between-groups difference in the estimated reduction of mortality due to lung cancer screening

    Time frame: 14 days

    Participants had 14 days to complete the survey

Secondary outcomes

  1. Between-groups difference prevalence of lung cancer

    Time frame: 14 days

    Participants had 14 days to complete the survey

  2. Between-groups difference in sensitivity of lung cancer screening

    Time frame: 14 days

    Participants had 14 days to complete the survey

  3. Between-groups difference in the frequency of a positive test result

    Time frame: 14 days

    Participants had 14 days to complete the survey

  4. Between-groups difference in specificity of lung cancer screening

    Time frame: 14 days

    Participants had 14 days to complete the survey

  5. Between-groups difference in positive predictive value of lung cancer screening

    Time frame: 14 days

    Participants had 14 days to complete the survey

  6. Between-groups difference in the false negative rate of lung cancer screening

    Time frame: 14 days

    Participants had 14 days to complete the survey

Sponsors and collaborators

Lead sponsor

Otto Wagner Hospital

Other

Registry information

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Sep 7, 2015
Registry last updated
Sep 7, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.